InvestorNewsBreaks – PaxMedica Inc. (PXMD) Announces Immediate Exercise of Warrants to Total Approximately $884K
September 3, 2024
PaxMedica (OTC: PXMD), a clinical-stage biopharmaceutical company dedicated to advancing treatments for neurological disorders, has entered into definitive agreements for the immediate exercise of certain outstanding warrants. The agreements outline the “purchase up to an aggregate of 4,423,080 shares of common stock of the originally issued in November 2023, having an exercise price of 1.30 […]
InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Provides Update on Its Response to Extraordinary Request to Provide PAX-101 to Malawi
August 27, 2024
PaxMedica (NASDAQ: PXMD), a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announced that the first patient suffering from the potentially fatal parasitic infection known as Human Africa Trypanosomiasis Brucei Rhodesiense (“HAT”) in Malawi had been treated with PAX-101, an intravenous form of Suramin. The announcement noted that the Malawi Ministry of […]
InvestorNewsBreaks – PaxMedica Inc. (PXMD) Committed to Global Health, Potential Positive Impact of PAX-101
August 22, 2024
PaxMedica (OTC: PXMD), a biopharmaceutical company specializing in neurological disorder treatments, is preparing to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration for suramin to treat Human African Trypanosomiasis (“HAT”). “In April 2024, PaxMedica underscored its commitment to global health by responding to an urgent request from Malawi for an […]
InvestorNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Preparing for NDA Submission for Leading Drug Candidate
August 5, 2024
PaxMedica (OTC: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, is in the process of preparing to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”). The NDA is for PAX-101, an intravenous formulation of suramin that could potentially treat conditions such as Human African Trypanosomiasis and […]
PaxMedica Inc. (NASDAQ: PXMD) Developing Treatments for Underserved Neurological Disorders
July 25, 2024
PaxMedica (NASDAQ: PXMD), a biopharmaceutical company specializing in neurological disorder treatments, is preparing to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for suramin to treat Human African Trypanosomiasis, a century-old treatment in East Africa. In April 2024, PaxMedica underscored its commitment to global health by responding to an […]
InvestorNewsBreaks – PaxMedica Inc. (PXMD) Intensifying Efforts to Achieve Significant Program Milestones
July 1, 2024
PaxMedica (OTC: PXMD), a biopharmaceutical company specializing in neurological disorders, is preparing to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for using suramin to treat Human African Trypanosomiasis (“HAT”), a well-established treatment in East Africa for nearly a century. A recent article discussed PaxMedica gearing up for a […]
InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Marks Major Milestone in Preparations for NDA Submission, Global Suramin Supply
June 13, 2024
PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, recently completed its three registration/validation batches of PAX-101, an IV formulation of suramin. “This accomplishment marks a significant step toward submitting a New Drug Application (‘NDA’) to the U.S. Food and Drug Administration (‘FDA’) in the fourth quarter of 2024. This step […]
PaxMedica Inc. (NASDAQ: PXMD) Shares Corporate Update and Commitment to Advancing Therapies for Neurological Disorders, Prepares for Key Engagements with the FDA
May 29, 2024
PaxMedica (NASDAQ: PXMD), a biopharmaceutical company specializing in neurological disorder treatments, recently shared corporate updates regarding its continued progress toward establishing suramin as an accepted treatment for Human African Trypanosomiasis (“HAT”). PaxMedica is preparing to submit a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) for using suramin to treat Human […]
PaxMedica Inc. (NASDAQ: PXMD) Seeking to Qualify for Neglected Tropical Disease Priority Review Voucher Program in Wake of Malawi Major Sleeping Sickness Crisis
May 24, 2024
PaxMedica (NASDAQ: PXMD), a biopharmaceutical firm dedicated to advancing treatments for neurological disorders, recently announced that it has received an urgent plea from the Ministry of Health (“MOH”) of Malawi. The MOH is requesting emergency access to IV suramin to prevent a potential humanitarian crisis due to dwindling supplies of essential drugs used to save […]
InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Dedicated to Ensuring Access to Life-Saving Treatments
May 22, 2024
PaxMedica (NASDAQ: PXMD), a renowned biopharmaceutical company specializing in treatments for neurological disorders, recently took swift action to address a pressing medical situation unfolding in Malawi, East Africa. “The Ministry of Health (‘MOH’) of Malawi has issued a plea for access to IV suramin, a vital medication in combating the life-threatening sleeping sickness crisis affecting […]
InvestorNewsBreaks — PaxMedica Inc. (PXMD) Appeals NASDAQ Delisting Decision, Prepares for June FDA Meeting
May 15, 2024
PaxMedica (OTC: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has filed a formal notice of appeal with the NASDAQ Office of Appeals and Review; the company is appealing to reverse the decision of the NASDAQ Hearings Panel to delist the company from. The company also announced that it has retained Jacob […]
PaxMedica Files Nasdaq Delisting Appeal Notice and Prepares for Upcoming FDA Meeting on PAX-101
May 15, 2024
TARRYTOWN, New York, May 15, 2024 (GLOBE NEWSWIRE) — via IBN — PaxMedica, Inc. (the “Company” or “PaxMedica”) (OTC: PXMD), a biopharmaceutical company dedicated to advancing treatments for neurological disorders, today announced it has timely filed a formal notice of appeal with the Nasdaq Office of Appeals and Review to reverse the decision of a Nasdaq […]
InvestorNewsBreaks – PaxMedica Inc. (PXMD) Continues Advancement of PAX-101 Regulatory Strategy
May 7, 2024
PaxMedica (OTC: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has issued a corporate update in light of its transition off the NASDAQ stock market, emphasizing this change will not affect the company’s commitment to advancing treatments for neurological disorders. “Our determination to progress with the NDA submission for PAX-101 remains unaffected, […]
PaxMedica Provides Company Update and Continues to Advance PAX-101 Regulatory Strategy
May 7, 2024
TARRYTOWN, New York, May 07, 2024 (GLOBE NEWSWIRE) — via IBN — PaxMedica, Inc. (OTC: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, provided a corporate update in light of its transition off the NASDAQ stock market, emphasizing this change will not affect the company’s commitment to advancing treatments for neurological disorders. Howard […]
PaxMedica Inc. (NASDAQ: PXMD) Announces PAX-101 Batch Completion for NDA Application to FDA
May 1, 2024
PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, recently announced that it has completed its three registration/validation batches of PAX-101, an IV formulation of suramin. This accomplishment marks a significant step toward submitting a New Drug Application (“NDA”) to the U.S. Food and Drug Administration (“FDA”) in the fourth quarter […]
InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Featured in Latest Bell2Bell Podcast Release
April 26, 2024
PaxMedica (NASDAQ: PXMD), a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, was featured in the latest episode of The Bell2Bell Podcast as part of IBN’s sustained effort to provide specialized content distribution via widespread syndication channels. Howard Weisman, CEO of PaxMedica, and Dr. Marshal Lemerani, Program Manager at the Malawi Ministry of […]
PaxMedica’s CEO and Malawi Health Official Discuss Urgent Medical Crisis in Bell2Bell Podcast
April 26, 2024
LOS ANGELES, April 26, 2024 (GLOBE NEWSWIRE) — via IBN — IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. PaxMedica (NASDAQ: PXMD), a biopharmaceutical company […]
“Urgent Action: PaxMedica Inc. (NASDAQ: PXMD) Addresses Medical Crisis in Malawi”
April 24, 2024
In recent developments, PaxMedica (NASDAQ: PXMD), a renowned biopharmaceutical company specializing in treatments for neurological disorders, has taken swift action to address a pressing medical situation unfolding in Malawi, East Africa. The Ministry of Health (“MOH”) of Malawi has issued a plea for access to IV suramin, a vital medication in combating the life-threatening sleeping […]
InvestorNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Completes Key Step in Preparation of PAX-101 for NDA Submission to FDA
April 24, 2024
PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has made a key announcement regarding the development of its proprietary PAX-101, an IV formulation of suramin. According to the announcement, the company has completed execution of three pivotal registration/validation batches of PAX-101. The company noted that the completion is an “important […]
InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Responds to Emergency Request for IV Suramin, Commits to Provide Immediate Access to PAX-101
April 23, 2024
PaxMedica (NASDAQ: PXMD), a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, expects to take immediate action in response to an urgent request for IV suramin from the Ministry of Health (“MOH”) of Malawi, a country in east Africa. The request seeks emergency access to PaxMedica’s recently completed registration batches of PAX-101 (“IV […]
PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
April 23, 2024
TARRYTOWN, New York, April 23, 2024 (GLOBE NEWSWIRE) — via IBN – PaxMedica Inc. (Nasdaq: PXMD) (the “Company”), a leading biopharmaceutical company dedicated to advancing treatments for neurological disorders, expects to take immediate action in response to an urgent request for IV suramin from the Ministry of Health (MOH) of Malawi, a country in east […]
InvestorNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) in Process of Responding to Emergency Request for IV Suramin from African Health Ministry
April 17, 2024
PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has received an urgent request from the Ministry of Health (“MOH”) of Malawi requesting emergency access to IV suramin. According to the announcement, Malawi officials requested the suramin in efforts to avert a potential humanitarian crisis brought on by dwindling supplies of […]
PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
April 17, 2024
TARRYTOWN, New York, April 16, 2024 (GLOBE NEWSWIRE) — via IBN — PaxMedica, Inc. (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced it has received an urgent request from the Ministry of Health (MOH) of Malawi, asking for emergency access to IV suramin to avert a potential humanitarian crisis brought on […]
PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission
April 15, 2024
TARRYTOWN, New York, April 11, 2024 (GLOBE NEWSWIRE) — via IBN – PaxMedica, Inc. (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the completed execution of its three pivotal registration/validation batches of PAX-101, an IV formulation of suramin. This achievement is an important milestone to enabling a New Drug Application (NDA) […]
InvestorNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Announces ‘Milestone Achievement’ on Journey to Developing PAX-101
April 12, 2024
PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has completed the execution of three pivotal registration/validation batches of PAX-101, which is an IV formulation of suramin. According to the announcement, this is an important milestone achievement as the company works toward enabling a New Drug Application (“NDA”) submission to the […]
InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Developing Robust Product Lineup to Address ASD, Associated Neurodevelopmental Conditions
April 5, 2024
PaxMedica (NASDAQ: PXMD) is a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms. The company is on a promising path to address the unmet medical needs of ASD, bringing hope to millions. “ASD is a […]
PaxMedica Inc. (NASDAQ: PXMD) Developing Pipeline to Address Unmet Needs in Autism Spectrum Disorder via Suramin Sodium
March 21, 2024
Researchers used to believe that autism spectrum disorder only affected one in 2,500 children – today, that estimation is closer to one in 36 children. Between 1998 and 2018, research has found more than a 780% increase in the number of autism cases in the United Kingdom. This significant increase is partially due to the […]
InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) on Promising Path to Meet Medical Needs of ASD Patients
March 20, 2024
PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (“APTs”), is focusing its lead program on autism spectrum disorder (“ASD”), for which there is no approved pharmacologic treatment targeting cause and symptoms. “The current ASD treatments only address the symptoms of the condition but do not target the pathophysiology […]
InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Shares Vision, Innovations in ASD Treatments in Updated Company Presentation
March 13, 2024
PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the release of its latest company presentation. The comprehensive overview showcases PaxMedica’s strategic direction, recent advancements in autism spectrum disorder (“ASD”) therapeutics, and its commitment to addressing unmet needs within the ASD community. “PaxMedica is pleased to share our vision […]
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments
March 13, 2024
TARRYTOWN, New York, March 13, 2024 (GLOBE NEWSWIRE) — via IBN – PaxMedica, Inc. (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced the release of its latest company presentation. This comprehensive overview showcases PaxMedica’s strategic direction, recent advancements in ASD therapeutics, and its commitment to addressing unmet needs within the ASD community. […]
PaxMedica Inc. (NASDAQ: PXMD) Pursues Autism Treatment as Diagnostic App Shows Promise to Effective ASD Diagnosis
March 8, 2024
According to the CDC, about 1 in 36 children are diagnosed with autism spectrum disorder (“ASD”) – with ASD four times more common among boys than girls (https://ibn.fm/06kly). Currently, there is no medical test to diagnose ASD, and families often face a delay in receiving a diagnosis. Doctors must rely on developmental history and the […]
InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Committed to Developing Groundbreaking Therapies, Transformative Solutions
March 1, 2024
PaxMedica (NASDAQ: PXMD) is a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms. The company is on a promising path to address unmet medical needs of ASD patients. “The prevalence of ASD in the United […]
PaxMedica Inc. (NASDAQ: PXMD) Developing Pipeline of Products to Address Prevalence and Unmet Medical Needs of Autism Spectrum Disorder
February 20, 2024
The prevalence of autism spectrum disorder (“ASD”) in the United States has risen to approximately 1 in 36 children, according to the Centers for Disease Control and Prevention (“CDC”). There are currently no approved pharmacologic treatments that target the causes and symptoms of ASD – the only treatment available on the market addresses symptoms of […]
InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Dedicated to Enhancing Quality of Life for Individuals Living with ASD
January 26, 2024
PaxMedica (NASDAQ: PXMD) recently released an insightful video detailing the outcomes of its Phase 2 study on autism spectrum disorder (“ASD”), initially published in the Annals of General Psychiatry. “This pivotal video highlights the research led by Chief Medical Officer Dr. David Hough and a team of ASD experts, and the potential of low-dose suramin […]
InvestorBrandNetwork Highlights PaxMedica Inc.’s (NASDAQ: PXMD) Video Release on Transformative ASD Study
January 16, 2024
In a significant development for the neurological disorder community, PaxMedica (NASDAQ: PXMD) has released an insightful video detailing the outcomes of its Phase 2 study on Autism Spectrum Disorder (“ASD”), initially published in the Annals of General Psychiatry. This pivotal video highlights the research led by Chief Medical Officer Dr. David Hough and a team […]
InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) on Promising Path to Address Unmet ASD Needs
January 12, 2024
PaxMedica (NASDAQ: PXMD) is a clinical-stage biopharmaceutical company focused on developing novel anti-purinergic therapies (“APTs”) for the treatment of autism spectrum disorder (“ASD”) and other serious conditions with intractable neurologic symptoms. “While ASD is not uncommon, there are no pharmaceutical treatments approved to treat the disorder, only to manage the symptoms – which creates an […]
InvestorNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Files 8-K Following Nasdaq Compliance Achievement
December 21, 2023
In a significant corporate update, PaxMedica (NASDAQ: PXMD) today filed an 8-K with the Securities and Exchange Commission, disclosing its successful compliance with Nasdaq’s minimum equity requirements. Journey Towards Compliance PaxMedica’s compliance journey began on December 6, 2022, when Nasdaq noted its inability to meet the Minimum Market Value of Listed Securities Requirement of $35 […]
PaxMedica Inc. (NASDAQ: PXMD) Fireside Chat with CEO Howard Weisman Sheds Light on Company Achievements for ASD Therapy Pipeline
December 18, 2023
In a 2020 report released by the Centers for Disease Control and Prevention (“CDC”), it was estimated that 1 out of 36 children had been diagnosed with autism spectrum disorder (“ASD”) in the United States. While ASD is not uncommon, there are no pharmaceutical treatments approved to treat the disorder, only to manage the symptoms […]
InvestorNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) CEO Featured in Just-Released Fireside Chat Video
December 6, 2023
PaxMedica (NASDAQ: PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, has released a fireside chat video with CEO and chair Howard Weisman. During the company update video, Weisman outlines the company’s recent achievement and reiterates PaxMedica’s focus on developing groundbreaking therapies and transformative solutions. Specifically, Weisman provided a summary of the company’s […]
PaxMedica Inc. (NASDAQ: PXMD) Completes Key Type-B FDA Meeting, Discussing Positive Results from PAX-HAT-301 Study
December 6, 2023
PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of Autism Spectrum Disorder (“ASD”) and other serious conditions with intractable neurologic symptoms, recently announced the completion of a type-B meeting with the Food and Drug Administration. During the live meeting, the company discussed the positive […]